Want to see IPHA full AI Analyst Report?
IPHA Stock Chart & Stats
$1.66
-$0.03(-1.61%)
At close: 4:00 PM EST
$1.66
-$0.03(-1.61%)
Day’s Range― - ―
52-Week Range$1.17 - $2.63
Previous CloseN/A
Volume6.24K
Average Volume (3M)386.19K
Market Cap
$178.59M
Enterprise Value$142.85M
Total Cash (Recent Filing)$34.30M
Total Debt (Recent Filing)$22.56M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Sep 17, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding93,921,860
10 Day Avg. Volume29,239
30 Day Avg. Volume386,189
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)-6.14
Price to Sales (P/S)47.79
P/FCF Ratio-3.81
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue51.26
Enterprise Value/Gross Profit51.26
Enterprise Value/Ebitda-2.56
Forecast
1Y Price Target
$6.50Price Target Upside291.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$36.26M
Bulls Say, Bears Say
Bulls Say
Partnerships & Milestone EconomicsLarge, structured partner deals provide durable non-dilutive funding potential, milestone and royalty upside, and risk-sharing on development/commercialization. This materially strengthens Innate's long-term cash optionality and reduces reliance on single-product success for financing.
Regulatory Progress For LacutamabFormal regulatory clearances and multiple expedited designations materially de-risk the development path for lacutamab, supporting a registrational trial design. Such regulatory status improves the probability of approval and future commercial optionality if supported financially.
Broad, Differentiated Clinical PipelineMultiple assets across modalities and stages (ADC, checkpoint modulators, partnered Phase III) create diversified clinical value drivers and reduce binary risk. Partner-led trials and scientific visibility increase optionality and potential for value realization via milestones or commercialization.
Bears Say
Negative Shareholders' EquityNegative equity signals cumulative losses that erode solvency and lender/partner confidence. Over the medium term this restricts financing options, elevates refinancing/dilution risk, and may force concessions on deal economics or timing of pivotal programs.
Short Cash RunwayA limited runway creates structural execution risk for initiating late-stage trials and sustaining multiple programs. Dependence on near-term financing or partner contributions can delay trials or force asset prioritization, harming long-term program timelines and optionality.
Low Revenue Versus High Operating SpendPersistent low internal revenue relative to high R&D/G&A undermines ability to self-fund development, increasing reliance on external capital and partner milestones. Over time this pressures margins, governance choices, and the ability to sustain a broad pipeline without dilutive financings.
Innate Pharma News
IPHA FAQ
What was Innate Pharma’s price range in the past 12 months?
Innate Pharma lowest stock price was $1.17 and its highest was $2.63 in the past 12 months.
What is Innate Pharma’s market cap?
Innate Pharma’s market cap is $178.59M.
When is Innate Pharma’s upcoming earnings report date?
Innate Pharma’s upcoming earnings report date is Sep 17, 2026 which is in 73 days.
How were Innate Pharma’s earnings last quarter?
Innate Pharma released its earnings results on Mar 26, 2026. The company reported -$0.358 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.216.
Is Innate Pharma overvalued?
According to Wall Street analysts Innate Pharma’s price is currently Undervalued.
Does Innate Pharma pay dividends?
Innate Pharma does not currently pay dividends.
What is Innate Pharma’s EPS estimate?
Innate Pharma’s EPS estimate is -0.21.
How many shares outstanding does Innate Pharma have?
Innate Pharma has 93,921,860 shares outstanding.
What happened to Innate Pharma’s price movement after its last earnings report?
Innate Pharma reported an EPS of -$0.358 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -2.344%.
Which hedge fund is a major shareholder of Innate Pharma?
Currently, no hedge funds are holding shares in IPHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innate Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (291.57% Upside)
$6.50 (291.57% Upside)
Blogger Sentiment
Bullish
IPHA Sentiment 100%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.68%
12-Months-Change
Fundamentals
Return on Equity
593.93%
Trailing 12-Months
Asset Growth
-35.95%
Trailing 12-Months
Company Description
Innate Pharma
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
IPHA Company Deck
IPHA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call featured multiple meaningful clinical and regulatory milestones (FDA clearance for lacutamab Phase III, completed PACIFIC-9 enrollment, encouraging early IPH4502 data, and high-value partnership milestone potential) and demonstrated cost discipline with lower R&D spend. Offsetting these positives are material near-term financing and execution risks: modest reported revenue (EUR 9M), a high burn rate (EUR 63M operating expenses), and a limited cash runway (EUR 44.8M through Q3 2026) that makes initiation of late-stage programs dependent on partner deals or other financing. Clinical data are promising but still early and need confirmation. Overall, the company shows strong programmatic momentum and partnership upside, but material funding and timing risks balance that optimism.View all IPHA earnings summariesIPHA Stock 12 Month Forecast
Average Price Target
$6.50
▲(291.57% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.09% Other Institutional Investors
99.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---